In what might be a glitch in the Cinderella Story of Ruxolitinib a/k/a Jakafi and Jakavi, a draft guidance from an NHS oversight body places into question the cost-effectiveness of the drug, the very first approved treatment for symptoms of myelofibrosis. Evaluating a drug based on its cost “per quality-adjusted life year,” is chilling to read but may be a fact of life in a time of shrinking budgets and rising demand.
Dr. Claire Harrison’s comments on the recommendations, immediately follow. Thanks to MPD Voice for posting this…and Chris Harper for making sure we saw it.
View the full MPD Voice document here in your browser